NASDAQ
Eucrates Biomedical Acquisition Corp. (EUCR) has a free cash flow growth of -774.69% as of Friday, May 29, 2026. This represents a 6526.16% decrease compared to its 12-month average of 12.06%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.